SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending downwards, with the community citing concerns around debt, dilution, and a potential AI bubble as reasons for the decline. Some traders are calling for a continued sell-off, while others believe the dip represents a buying opportunity based on the company's long-term potential in AI data centers. Overall sentiment is mixed, with many expressing frustration over recent losses.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending amidst discussions around its future financial guidance and potential acquisitions, with the community actively debating the company's direction and whether it represents a long-term investment opportunity. Some traders are weighing in on option strategies, while others express frustration with the stock's perceived lack of movement. Broader market narratives, including the performance of other pharmaceutical stocks and potential impacts from regulatory actions, are also influencing the conversation.

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending due to significant price volatility and high trading volume, sparking discussions around potential short squeezes. Community members are actively debating resistance levels, halt patterns, and potential price targets, with some comparing it to past high-momentum stocks. The stock's connection to the robotics sector and AI is also fueling interest, though some caution against potential pump-and-dump schemes.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation and rumors of potential rescheduling of cannabis, fueled by comments from political figures. The community is buzzing with anticipation of an executive order, with many believing it could trigger a significant short squeeze. Discussions also include Tilray's profitability and its potential to benefit from broader cannabis market developments.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending as the stock experiences significant volatility, with community members debating whether recent price drops represent a buying opportunity or a sign of deeper issues. Discussions include the company's growth potential in the AI and data center space, its relationship with major players like Microsoft and Meta, and concerns about market conditions.

Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Biodexa Pharmaceuticals Plc - ADR

Biodexa Pharmaceuticals Plc

BDRX is trending due to a circuit breaker halt and resulting momentum, with community members citing its low float as a catalyst for potential further gains. Discussions revolve around potential price targets, with some suggesting the stock could reach significantly higher values. The stock is also appearing on top gainers lists, attracting attention from traders looking for quick profits.

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Aldeyra Therapeutics Inc

ALDX is trending due to the FDA's extended review timeline for its dry eye disease drug, Reproxalap, with a new PDUFA date in March 2026. While the extension triggered a price drop, the community is debating whether this is a procedural delay or indicates deeper issues with the application, with some speculating about approval being priced in. Bullish sentiment remains due to expectations of eventual approval and potential acquisition by AbbVie.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is experiencing a significant downturn, sparking debates about its valuation and the AI sector's overall health. Community discussions range from dip-buying optimism fueled by Cathie Wood's purchases, to concerns over debt, insider selling, and delayed data center projects. Bearish sentiment is rising amid broader market anxieties and AI bubble fears, with some predicting further declines.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

CIFR is trending as investors assess its potential amid volatility in the data center sector, with community members debating whether the recent downturn presents an opportunity or signals further declines. Discussions also involve the stock's correlation with Bitcoin and its positioning within the broader AI infrastructure landscape. Some traders are closely watching for a breakout above key resistance levels.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending due to a reported consideration to halt F-150 Lightning production amidst EV sector losses, sparking discussions on their EV strategy pivot and potential benefits from shifting focus. The community is weighing the implications of this strategic shift amid mixed opinions on the company's direction. Broader conversations encompass topics around ICE vs EV vehicles.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Liontrust Investment Partners LLP Cuts Position in Alnylam Pharmaceuticals, Inc. $ALNY

Liontrust Investment Partners LLP trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 32.4% in the second quarter, according to its most recent disclosure...

Holocene Advisors LP Invests $194.62 Million in Alnylam Pharmaceuticals, Inc. $ALNY

Holocene Advisors LP bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities...

China Universal Asset Management Co. Ltd. Trims Position in Alnylam Pharmaceuticals, Inc. $ALNY

China Universal Asset Management Co. Ltd. reduced its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 10.2% in the 2nd quarter, according to its most recent filing with the...

Gilder Gagnon Howe & Co. LLC Sells 8,487 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Gilder Gagnon Howe & Co. LLC reduced its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 2.5% during the 2nd quarter, according to its most recent filing with the Securities...

Eventide Asset Management LLC Sells 40,548 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Eventide Asset Management LLC lowered its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 24.4% in the 2nd quarter, according to its most recent 13F filing with the...

Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Bellevue Group AG

Bellevue Group AG cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 11.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange...

Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options

Investors need to pay close attention to ALNY stock based on the movements in the options market lately. 

Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $508.00

Stifel Nicolaus increased their price target on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a "buy" rating in a report on Thursday...

WINTON GROUP Ltd Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY

WINTON GROUP Ltd bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The...

Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027

Alnylam Pharmaceuticals, Inc. (Alnylam) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has entered into separate, privately negotiated repurchase agreements with...

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Current Price	$393.04
Prev Close	$391.50
Open	$391.11
Dividend Yield	0.00%
50-Day Moving Average	$451.30
Beta	0.89
Avg. Volume	973,283.42
PE Ratio	1,628.54

52-Week High	$495.55
52-Week Low	$205.87
Market Capitalization	$51.72B
EPS (Annual)	-$2.18
Price to Book	220.60
Revenue Per Employee	$1.01M
Enterprise Value/EBITDA	N/A

ALNY
Alnylam Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALNY News

ALNYAlnylam Pharmaceuticals Inc